Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Net Assets
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has net assets worth CN¥9.20 Billion CNY (≈ $1.35 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.81 Billion ≈ $2.02 Billion USD) and total liabilities (CN¥4.62 Billion ≈ $675.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Zhejiang Hisun Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.20 Billion |
| % of Total Assets | 66.57% |
| Annual Growth Rate | 14.83% |
| 5-Year Change | 20.5% |
| 10-Year Change | 10.11% |
| Growth Volatility | 39.47 |
Zhejiang Hisun Pharmaceutical Co Ltd - Net Assets Trend (1997–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Zhejiang Hisun Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual net assets of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025. For live valuation and market cap data, see Zhejiang Hisun Pharmaceutical Co Ltd (600267) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.85 Billion ≈ $1.30 Billion |
+3.18% |
| 2024-12-31 | CN¥8.58 Billion ≈ $1.26 Billion |
+2.75% |
| 2023-12-31 | CN¥8.35 Billion ≈ $1.22 Billion |
+0.23% |
| 2022-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
+13.41% |
| 2021-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
-11.03% |
| 2020-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
+7.47% |
| 2019-12-31 | CN¥7.68 Billion ≈ $1.12 Billion |
+4.12% |
| 2018-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
-6.31% |
| 2017-12-31 | CN¥7.88 Billion ≈ $1.15 Billion |
-2.04% |
| 2016-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
-1.54% |
| 2015-12-31 | CN¥8.17 Billion ≈ $1.19 Billion |
-1.20% |
| 2014-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
+38.71% |
| 2013-12-31 | CN¥5.96 Billion ≈ $871.87 Million |
+14.63% |
| 2012-12-31 | CN¥5.20 Billion ≈ $760.59 Million |
+13.15% |
| 2011-12-31 | CN¥4.59 Billion ≈ $672.18 Million |
+67.39% |
| 2010-12-31 | CN¥2.74 Billion ≈ $401.57 Million |
+12.90% |
| 2009-12-31 | CN¥2.43 Billion ≈ $355.67 Million |
+56.89% |
| 2008-12-31 | CN¥1.55 Billion ≈ $226.70 Million |
+12.51% |
| 2007-12-31 | CN¥1.38 Billion ≈ $201.50 Million |
+8.38% |
| 2006-12-31 | CN¥1.27 Billion ≈ $185.92 Million |
+3.47% |
| 2005-12-31 | CN¥1.23 Billion ≈ $179.69 Million |
+2.16% |
| 2004-12-31 | CN¥1.20 Billion ≈ $175.90 Million |
+19.99% |
| 2003-12-31 | CN¥1.00 Billion ≈ $146.59 Million |
+21.45% |
| 2002-12-31 | CN¥824.83 Million ≈ $120.70 Million |
+5.18% |
| 2001-12-31 | CN¥784.18 Million ≈ $114.75 Million |
+3.47% |
| 2000-12-31 | CN¥757.90 Million ≈ $110.90 Million |
+203.31% |
| 1999-12-31 | CN¥249.88 Million ≈ $36.56 Million |
+27.16% |
| 1998-12-31 | CN¥196.50 Million ≈ $28.75 Million |
+6.66% |
| 1997-12-31 | CN¥184.23 Million ≈ $26.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Hisun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 283340564942.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.83 Billion | 32.92% |
| Other Components | CN¥5.77 Billion | 67.08% |
| Total Equity | CN¥8.61 Billion | 100.00% |
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
$2.12 Billion |
|
Bavarian Nordic
CO:BAVA
|
$2.12 Billion |
|
H&R Real Estate Investment Trust
TO:HR-UN
|
$2.12 Billion |
|
Netcompany Group A/S
CO:NETC
|
$2.12 Billion |
|
Zhuzhou CRRC Times Electric Co. Ltd
F:ZTX
|
$2.12 Billion |
|
Jones Tech PLC Class A
SHE:300684
|
$2.11 Billion |
|
Anyuan Coal Industry Group Co Ltd
SHG:600397
|
$2.11 Billion |
|
Axogen Inc
NASDAQ:AXGN
|
$2.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Hisun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,341,353,163 to 8,607,245,943, a change of 265,892,780 (3.2%).
- Net income of 540,707,781 contributed positively to equity growth.
- Dividend payments of 343,424,483 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥540.71 Million | +6.28% |
| Dividends Paid | CN¥343.42 Million | -3.99% |
| Other Changes | CN¥68.61 Million | +0.8% |
| Total Change | CN¥- | 3.19% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Hisun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 47.40x to 1.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.25 | CN¥12.06 | x |
| 1998-12-31 | CN¥0.27 | CN¥12.06 | x |
| 1999-12-31 | CN¥0.33 | CN¥12.06 | x |
| 2000-12-31 | CN¥1.04 | CN¥12.06 | x |
| 2001-12-31 | CN¥1.07 | CN¥12.06 | x |
| 2002-12-31 | CN¥1.12 | CN¥12.06 | x |
| 2003-12-31 | CN¥1.36 | CN¥12.06 | x |
| 2004-12-31 | CN¥1.64 | CN¥12.06 | x |
| 2005-12-31 | CN¥1.69 | CN¥12.06 | x |
| 2006-12-31 | CN¥1.74 | CN¥12.06 | x |
| 2007-12-31 | CN¥1.90 | CN¥12.06 | x |
| 2008-12-31 | CN¥2.11 | CN¥12.06 | x |
| 2009-12-31 | CN¥3.30 | CN¥12.06 | x |
| 2010-12-31 | CN¥3.50 | CN¥12.06 | x |
| 2011-12-31 | CN¥5.45 | CN¥12.06 | x |
| 2012-12-31 | CN¥5.60 | CN¥12.06 | x |
| 2013-12-31 | CN¥5.83 | CN¥12.06 | x |
| 2014-12-31 | CN¥7.98 | CN¥12.06 | x |
| 2015-12-31 | CN¥5.10 | CN¥12.06 | x |
| 2016-12-31 | CN¥7.15 | CN¥12.06 | x |
| 2017-12-31 | CN¥7.03 | CN¥12.06 | x |
| 2018-12-31 | CN¥6.40 | CN¥12.06 | x |
| 2019-12-31 | CN¥6.50 | CN¥12.06 | x |
| 2020-12-31 | CN¥6.92 | CN¥12.06 | x |
| 2021-12-31 | CN¥6.43 | CN¥12.06 | x |
| 2022-12-31 | CN¥7.01 | CN¥12.06 | x |
| 2023-12-31 | CN¥6.96 | CN¥12.06 | x |
| 2024-12-31 | CN¥7.21 | CN¥12.06 | x |
| 2025-12-31 | CN¥7.18 | CN¥12.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Hisun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.28%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.13%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.75x
- Recent ROE (6.28%) is below the historical average (8.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 28.82% | 19.50% | 0.76x | 1.94x | CN¥34.32 Million |
| 1998 | 24.32% | 16.68% | 0.59x | 2.49x | CN¥27.85 Million |
| 1999 | 21.06% | 13.82% | 0.53x | 2.86x | CN¥25.98 Million |
| 2000 | 6.86% | 9.85% | 0.43x | 1.62x | CN¥-23.37 Million |
| 2001 | 6.35% | 8.43% | 0.44x | 1.70x | CN¥-27.94 Million |
| 2002 | 6.24% | 6.57% | 0.48x | 1.96x | CN¥-30.15 Million |
| 2003 | 17.42% | 10.96% | 0.83x | 1.92x | CN¥72.39 Million |
| 2004 | 18.50% | 12.21% | 0.82x | 1.86x | CN¥99.81 Million |
| 2005 | 9.58% | 6.08% | 0.73x | 2.15x | CN¥-5.11 Million |
| 2006 | 6.60% | 3.57% | 0.82x | 2.25x | CN¥-42.44 Million |
| 2007 | 10.25% | 4.92% | 0.95x | 2.19x | CN¥3.37 Million |
| 2008 | 12.91% | 6.14% | 0.77x | 2.72x | CN¥43.98 Million |
| 2009 | 11.39% | 6.80% | 0.77x | 2.17x | CN¥33.18 Million |
| 2010 | 13.56% | 8.05% | 0.77x | 2.19x | CN¥95.95 Million |
| 2011 | 11.20% | 9.77% | 0.63x | 1.83x | CN¥54.04 Million |
| 2012 | 6.43% | 5.19% | 0.55x | 2.26x | CN¥-167.31 Million |
| 2013 | 6.18% | 3.51% | 0.62x | 2.86x | CN¥-186.82 Million |
| 2014 | 4.38% | 3.05% | 0.58x | 2.46x | CN¥-394.50 Million |
| 2015 | 0.20% | 0.15% | 0.46x | 2.77x | CN¥-678.39 Million |
| 2016 | -1.40% | -0.97% | 0.47x | 3.07x | CN¥-769.94 Million |
| 2017 | 0.20% | 0.13% | 0.49x | 3.22x | CN¥-658.69 Million |
| 2018 | -7.96% | -4.83% | 0.47x | 3.53x | CN¥-1.11 Billion |
| 2019 | 1.48% | 0.84% | 0.52x | 3.42x | CN¥-534.35 Million |
| 2020 | 6.25% | 3.67% | 0.54x | 3.12x | CN¥-250.67 Million |
| 2021 | 6.67% | 4.01% | 0.63x | 2.65x | CN¥-243.44 Million |
| 2022 | 6.05% | 4.06% | 0.64x | 2.32x | CN¥-319.05 Million |
| 2023 | -1.15% | -0.90% | 0.59x | 2.17x | CN¥-903.37 Million |
| 2024 | 7.21% | 6.14% | 0.61x | 1.91x | CN¥-232.95 Million |
| 2025 | 6.28% | 5.13% | 0.70x | 1.75x | CN¥-320.02 Million |
Industry Comparison
This section compares Zhejiang Hisun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $7,126,136,237
- Average return on equity (ROE) among peers: 5.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical Co Ltd (600267) | CN¥9.20 Billion | 28.82% | 0.50x | $2.12 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $623.73 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $366.51 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.02 Billion | -4.54% | 0.16x | $4.83 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.64 Billion |
| Wedge Industrial Co Ltd (000534) | $1.55 Billion | 5.79% | 0.56x | $1.96 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.34 Billion | 14.39% | 0.44x | $13.50 Billion |
| Hainan Haiyao Co Ltd (000566) | $265.38 Million | 9.41% | 0.86x | $966.31 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $259.16 Million | -10.12% | 1.64x | $278.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $889.22 Million | 5.34% | 2.43x | $981.49 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.20 Billion |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more